DF/HCC Myeloma SPORE - CEP & DRP RFAs

July 28, 2022

The DF/HCC Lymphoma and Myeloma Program has released RFA's for its Myeloma SPORE Career Enhancement and Developmental Research Project Awards. Read more about these awards below for more information.

Career Enhancement Program RFA

The DF/HCC Myeloma Specialized Program in Research Excellence (SPORE) seeks applications for Career Enhancement and Developmental Project Awards in Myeloma.

REQUEST FOR APPLICATIONS: Career Enhancement Awards in Myeloma Research
AWARD AMOUNT:

up to $50,000 direct costs for one year

KEY DATES

APPLICATION DEADLINE: On or before August 26, 2022, 5:00 pm

Eligibility: Funds from this program may be used to support junior faculty or established investigators who wish to enhance or refocus their careers on translational research. CEP awardees are expected to interact with SPORE-associated translational research advisors to guide the project and monitor progress. This program is not a training program and does not support pre- or post-doctoral fellows, irrespective of whether they are working in the pre-clinical or clinical domain. However, advanced post-doctoral or clinical fellows who provide a letter from an institution stating that the candidate will be joining its faculty within the year are eligible for this program. Investigators supported by NCI career development awards (K series) may also be eligible for support through this program.

Application Materials: The eligible candidates are requested to submit an electronic version of the completed application in a single-file-pdf format to daniel_mcdermott@dfci.harvard.edu on or before August 26, 2022 at 5pm. See the full RFA for complete information. 

Hide

Developmental Research Project RFA

The DF/HCC Myeloma Specialized Program in Research Excellence (SPORE) seeks applications for Career Enhancement and Developmental Project Awards in Myeloma.

REQUEST FOR APPLICATIONS: Developmental Research Project Awards in Myeloma Research
AWARD AMOUNT: up to $100,000 direct costs for one year
KEY DATES:

APPLICATION DEADLINE: On or before August 26, 2022, 5:00 pm

Eligibility: Candidates may be either clinicians with an MD degree who are interested in translational research, or scientists with a PhD degree (or an equivalent higher degree), who are interested in the application of basic science to the problem of therapy of myeloma.  

Application Materials: An electronic version of the application, in single-page-pdf format only, should be sent to daniel_mcdermott@dfci.
harvard.edu
 on or before August 26, 2022 at 5pm. See the full RFA for complete information.

Hide